Specific Inhibition of GSK-3β by Tideglusib: Potential Therapeutic Target for Neuroblastoma Cancer Stem Cells
Bahmad, H. F.; Chalhoub, R. M.; Harati, H.; Bou-Gharios, J.; Ballout, F.; Monzer, A.; Msheik, H.; Assi, S.; Araji, T.; Elajami, M. K.; Ghanem, P.; Chamaa, F.; Kadara, H.; Abou-Antoun, T.; Daoud, G.; Fares, Y.; Abou-Kheir, W.
Show abstract
Neuroblastoma is an embryonic tumor that represents the most common extracranial solid tumor in children. Resistance to therapy is attributed, in part, to the persistence of a subpopulation of slowly dividing cancer stem cells (CSCs) within those tumors. Glycogen synthase kinase (GSK)-3{beta} is an active proline-directed serine/threonine kinase, well-known to be involved in different signaling pathways entangled in the pathophysiology of neuroblastoma. This study aims to assess the potency of an irreversible GSK-3{beta} inhibitor drug, Tideglusib (TDG), in suppressing proliferation, viability, and migration of human neuroblastoma cell lines, as well as its effects on their CSCs subpopulation in vitro and in vivo. Our results showed that treatment with TDG significantly reduced cell proliferation, viability, and migration of SK-N-SH and SH-SY5Y cells. TDG also significantly inhibited neurospheres formation capability in both cell lines, eradicating the self-renewal ability of highly resistant CSCs. Importantly, TDG potently inhibited neuroblastoma tumor growth and progression in vivo. In conclusion, TDG proved to be an effective in vitro and in vivo treatment for neuroblastoma cell lines and may hence serve as a potential adjuvant therapeutic agent for this aggressive nervous system tumor.
Matching journals
The top 12 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Preclinical assessment of MAGMAS inhibitor as a potential therapy for pediatric medulloblastoma 96%
- P16 methylation increases the sensitivity of cancer cells to the CDK4/6 inhibitor palbociclib 94%
- A Priori Activation of Apoptosis Pathways of Tumor (AAAPT) Technology: Development of Targeted Apoptosis Initiators for Cancer Treatment. 94%
Similar papers in this journal
- Chemogenomic screening Identifies the Hsp70 Co-chaperone HDJ2 as a Hub for Anticancer Drug Resistance 94%
- Cannabidiol (CBD) as a novel inhibitor of HLA-G expression in human choriocarcinoma cell line (JEG-3) 94%
- Novel Adult Cortical Neuron Processing and Screening method illustrates Sex- and Age-dependent effects of pharmaceutical compounds 94%
Similar papers in this journal
- Cyclopamine sensitizes Glioblastoma cells to Temozolomide treatment through Sonic Hedgehog pathway 96%
- KHDRBS3 facilitates self-renewal and temozolomide resistance of glioblastoma cell lines 95%
- Metabolic reprogramming and synergistic cytotoxicity of genistein and chemotherapy in human breast cancer cells 92%
Similar papers in this journal
- Ursolic acid inhibits cell migration and promotes JNK-dependent lysosomal associated cell death in Glioblastoma multiforme cells 93%
- Correlating basal gene expression across chemical sensitivity data to screen for novel synergistic interactors of HDAC inhibitors in pancreatic carcinoma 92%
- MiR-182-5p regulates Nogo-A expression and promotes neurite outgrowth of hippocampal neurons in vitro 91%
Similar papers in this journal
- LNX1 Modulates Notch1 Signaling to Promote Expansion of the Glioma Stem Cell Population During Temozolomide Therapy in Glioblastoma 94%
- Profiling anti-apoptotic protein BCL-xL expression in U-87 MG glioblastoma cells and patient-derived tumorspheres 94%
- The MEK1/2 pathway as a therapeutic target in high-grade serous ovarian carcinoma 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.